Media inquiries: media@celsiustx.com
Investor inquiries: investor@celsiustx.com
You are now leaving Celsius Therapeutics to visit a third-party website, which is solely responsible for all content and privacy policies.
September 23
Cambridge, MA – September 23, 2019 – Celsius Therapeutics, a company focused on bringing personalized medicine to patients with cancer, autoimmunity and other complex diseases, today announced that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the […]
September 19
Celsius Applying its Single-Cell Genomics Platform Across Multiple Tumor Types and Immuno-Oncology Clinical Trials CAMBRIDGE, Mass., September 19, 2019 – Celsius Therapeutics, a company focused on bringing personalized medicine to patients with cancer, autoimmunity and other complex diseases, today announced the signing of collaboration agreements with the Parker Institute for Cancer Immunotherapy (San Francisco, USA), Institut […]
July 9
Celsius to Apply its Single-Cell Genomics and Machine Learning Platform at Unprecedented Scale in Large Phase 2 Clinical Study CAMBRIDGE, Mass., July 9, 2019 – Celsius Therapeutics, a company focused on the discovery and development of precision therapeutics for patients with autoimmune diseases and cancer, today announced a collaboration with Janssen Biotech, Inc. Under the terms […]
June 11
Experienced biopharma leader brings business development, strategy and company-building expertise to accelerate Celsius’ growth
May 22
Greg Ryslik, Ph.D., Appointed to Chief Data Officer
Michael Boretti, Ph.D., Appointed to Chief Business Officer
May 15
Company Created to Understand the Cellular Ecosystem of Disease Through Single-Cell Genomics
Media inquiries: media@celsiustx.com
Investor inquiries: investor@celsiustx.com
You are now leaving Celsius Therapeutics to visit a third-party website, which is solely responsible for all content and privacy policies.